Abstract: A nontoxic anticancer compound is a derivative of 20-O-?-(D-glucopyranosyl)-20(S)-protopanaxadiol (CK) having at least one of the glucose hydroxyl groups replaced with at least one acetal group. The derivative enhances binding to a mitochondrial membrane protein and is more cytotoxic to cancerous cells than CK. The derivative can be an acetal of an unsubstituted or substituted aromatic group, such as an acetal formed from a substituted 1-(dimethoxymethyl)-benzene. One or more of the CK derivative (CKD) anticancer compounds can be used as an active portion of an anticancer medicament.

Abstract: Compositions and methods for reducing, or inhibiting bone loss in a subject in need thereof have been developed. Pharmaceutical compositions including one or more osteogenic compounds, or functional derivatives thereof, in an effective amount to reduce, or inhibit bone loss, or promote bone formation, preferably via stimulation of osteoblast differentiation, are provided. The compositions are particularly suited for treating bone loss associated with osteoporosis. Methods for treating, or preventing bone loss using the composition, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents, or procedures, are described.

Abstract: Pertains to the design and applications of platinum (II) compounds supported by a bidentate and N-heterocyclic carbene ligands. The Pt (II) complexes exhibit strong emission intensity differences when contacted with matched and mismatched DNA. In addition, the Pt (II) complexes show a color tunable effect when exposed to mismatched compared to matched DNA, which color effect can be easily detected.

Abstract: The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selectively prevent gene transcription and expression in a sequence-specific manner. In particular, this invention is directed to the selective inhibition of protein biosynthesis via antisense strategy using oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length. Particularly this invention relates to the use of antisense oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length, to hybridize to complementary RNA such as cellular messenger RNA, viral RNA, etc.

Abstract: The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selectively prevent gene transcription and expression in a sequence-specific manner. In particular, this invention is directed to the selective inhibition of protein biosynthesis via antisense strategy using oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length. Particularly this invention relates to the use of antisense oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length, to hybridize to complementary RNA such as cellular messenger RNA, viral RNA, etc.